134
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Omental metastases in patients with pseudomyxoma peritonei or colorectal peritoneal metastases – is routine omentectomy justified?

ORCID Icon, , , ORCID Icon &
Article: 2372356 | Received 28 Feb 2024, Accepted 20 Jun 2024, Published online: 27 Jun 2024

References

  • Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):1–8. doi: 10.1245/s10434-008-9966-2.
  • Huang C-Q, Min Y, Wang S-Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget. 2017;8(33):55657–55683. doi: 10.18632/oncotarget.17497.
  • Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–2456. doi: 10.1200/JCO.2011.39.7166.
  • Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg. 1994;219(2):109–111. doi: 10.1097/00000658-199402000-00001.
  • Sugarbaker PH, Chang D. Anatomic sites of disease in colorectal cancer patients recorded at the time of cytoreductive surgery for peritoneal metastases. Eur J Surg Oncol. 2022;48(5):946–955. doi: 10.1016/j.ejso.2022.01.012.
  • Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29–42. doi: 10.1097/00000658-199501000-00004.
  • Koppe MJ, Nagtegaal ID, de Wilt JH, et al. Recent insights into the pathophysiology of omental metastases. J Surg Oncol. 2014;110(6):670–675. doi: 10.1002/jso.23681.
  • Morison R. Remarks on some functions of the omentum. Br Med J. 1906;1(2350):76–78. doi: 10.1136/bmj.1.2350.76.
  • Hagiwara A, Takahashi T, Sawai K, et al. Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res. 1993;53(3):687–692.
  • Wolters U, Wolf T, Stützer H, et al. ASA classification and perioperative variables as predictors of postoperative outcome. Br J Anaesth. 1996;77(2):217–222. doi: 10.1093/bja/77.2.217.
  • Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–374. doi: 10.1007/978-1-4613-1247-5_23.
  • Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6(8):790–796. doi: 10.1007/s10434-999-0790-0.
  • González-Moreno S, González-Bayón LA, Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol. 2010;2(2):68–75. doi: 10.4251/wjgo.v2.i2.68.
  • Bosman F, Carniero F, Hruban R, et al. World Health Organisation classification of tumours of the digestive system. Lyon: IARC Press; 2010.
  • Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei. Am J Surg Pathol. 1995;19(12):1390–1408. doi: 10.1097/00000478-199512000-00006.
  • Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol. 2016;40(1):14–26. doi: 10.1097/PAS.0000000000000535.
  • Nors J, Iversen LH, Nielsen K, et al. Peritoneal metastases found in routinely resected specimens after cytoreductive surgery and heated intraperitoneal chemotherapy. Eur J Surg Oncol. 2022;48(4):795–802. doi: 10.1016/j.ejso.2021.12.026.
  • Bhatt A, Yonemura Y, Mehta S, et al. Target region resection in patients undergoing cytoreductive surgery for peritoneal metastases-is it necessary in absence of visible disease? Eur J Surg Oncol. 2020;46(4 Pt A):582–589. doi: 10.1016/j.ejso.2019.11.495.
  • Bonnefoy I, Mohamed F, Bonnot P-E, et al. Risk of omental metastases in patients undergoing cytoreductive surgery for colorectal peritoneal metastases. Dis Colon Rectum. 2020;63(9):1251–1256. doi: 10.1097/DCR.0000000000001670.
  • Khan S, Doan N-H, Hosseini M, et al. Is routine omentectomy a necessary component of cytoreductive surgery and HIPEC? Ann Surg Oncol. 2023;30(2):768–773. doi: 10.1245/s10434-022-12714-7.
  • Enblad M, Birgisson H, Wanders A, et al. Importance of absent neoplastic epithelium in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(4):1149–1156. doi: 10.1245/s10434-015-4989-y.
  • Al-Azzawi M, Misdraji J, van Velthuysen M-LF, et al. Acellular mucin in pseudomyxoma peritonei of appendiceal origin: what is adequate sampling for histopathology? J Clin Pathol. 2020;73(4):220–222. doi: 10.1136/jclinpath-2019-206213.
  • Evers DJ, Smeenk RM, Bottenberg PD, et al. Effect of preservation of the right gastro-epiploic artery on delayed gastric emptying after cytoreductive surgery and HIPEC: a randomized clinical trial. Eur J Surg Oncol. 2011;37(2):162–167. doi: 10.1016/j.ejso.2010.12.005.